Levothyroxine Treatment in Elderly Post-MI Patients with Overt Hypothyroidism

Rationale for Treatment

• The American Medical Association recommends initiating levothyroxine therapy for patients with TSH >10 mIU/L, as this level carries approximately 5% annual risk of progression and is associated with increased cardiovascular risk 1
• Untreated overt hypothyroidism can cause cardiac dysfunction including delayed relaxation and abnormal cardiac output, potentially worsening heart failure risk 2, 1

Critical Safety Considerations for Post-MI Patients

• For elderly patients (>70 years) or those with cardiac disease, the recommended starting dose is 25-50 mcg/day 1
• Even therapeutic doses of levothyroxine can unmask or worsen cardiac ischemia in elderly patients with underlying coronary disease 1

Cardiac Monitoring Requirements

• Consider ECG monitoring to screen for atrial fibrillation, especially given age >60 years 1

Critical Pitfalls to Avoid

• Approximately 25% of patients are inadvertently maintained on excessive doses that suppress TSH completely, increasing risks for atrial fibrillation, osteoporosis, and cardiac complications 1
• Starting thyroid hormone before corticosteroids in patients with concurrent adrenal insufficiency can precipitate life-threatening adrenal crisis 1

Monitoring Protocol

• Recheck TSH and free T4 in 6-8 weeks after starting therapy 1
• Once stable on maintenance dose, monitor TSH every 6-12 months 1
• For patients with cardiac disease, consider more frequent monitoring within 2 weeks if cardiac symptoms develop 1